29.76

4.17% -1.2673

Arcutis Biotherapeutics Inc (ARQT)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ARQT? Forum Prognose

Schlusskurs vom Vortag:

$31.03

Offen:

$30.85

24-Stunden-Volumen:

1.56M

Relative Volume:

0.69

Marktkapitalisierung:

$3.63B

Einnahmen:

$59.61M

Nettoeinkommen (Verlust:

$-262.14M

KGV:

-7.5925

EPS:

-3.92

Netto-Cashflow:

$-247.49M

1W Leistung:

+1.04%

1M Leistung:

+22.72%

6M Leistung:

+109.25%

1J Leistung:

+136.37%

1-Tages-Spanne:

$29.33

$31.12

1-Wochen-Bereich:

$29.28

$31.77

52-Wochen-Spanne:

$11.13

$31.77

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Firmenname

Arcutis Biotherapeutics Inc

Sektor

Healthcare (1139)

Branche

Biotechnology (634)

Telefon

805-418-5006

Adresse

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Mitarbeiter

342

Twitter

@ArcutisBio

Nächster Verdiensttermin

2024-12-06

Neueste SEC-Einreichungen

ARQT's Discussions on Twitter

Vergleichen Sie ARQT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ARQT Arcutis Biotherapeutics Inc	29.65	3.80B	59.61M	-262.14M	-247.49M	-3.92
VRTX Vertex Pharmaceuticals Inc	437.92	112.15B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	699.15	73.91B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	418.13	56.81B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	893.47	55.46B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	193.88	41.92B	447.02M	-1.18B	-906.14M	-6.1812

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-25	Eingeleitet	Goldman	Neutral
2024-12-30	Eingeleitet	H.C. Wainwright	Buy
2024-08-28	Eingeleitet	Jefferies	Buy
2024-01-03	Hochstufung	Mizuho	Neutral → Buy
2023-10-26	Herabstufung	Mizuho	Buy → Neutral
2023-10-13	Herabstufung	Goldman	Buy → Neutral
2022-09-07	Eingeleitet	Needham	Buy
2022-03-17	Eingeleitet	Goldman	Buy
2021-06-30	Eingeleitet	Mizuho	Buy
2021-05-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-11-09	Hochstufung	Goldman	Neutral → Buy
2020-10-08	Eingeleitet	Truist	Buy
2020-02-25	Eingeleitet	Cantor Fitzgerald	Overweight
2020-02-25	Eingeleitet	Cowen	Outperform
2020-02-25	Eingeleitet	Goldman	Neutral
2020-02-25	Eingeleitet	Guggenheim	Buy

Alle ansehen

Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten

07:36 AM

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected - simplywall.st

07:36 AM

07:21 AM

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri - BioSpace

07:21 AM

Dec 08, 2025

Arcutis Biotherapeutics Appoints Amit Munshi as New Director - TipRanks

Dec 08, 2025

Arcutis Biotherapeutics Announces Board Changes - TradingView

Dec 08, 2025

Amit Munshi joins Arcutis board as founder Chaudhuri retires By Investing.com - Investing.com India

Dec 08, 2025

Arcutis strengthens board of directors with new appointment of Amit Munshi - marketscreener.com

Dec 08, 2025

Arcutis Strengthens Board of Directors with New Appointment - GlobeNewswire

Dec 08, 2025

Arcutis Biotherapeutics | 12/8/25 - Channel 13 Las Vegas News KTNV

Dec 08, 2025

Arcutis Biotherapeutics: The Earnings Inflection Has Arrived (ARQT) - Seeking Alpha

Dec 08, 2025

Dec 07, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 07, 2025

Dec 06, 2025

Arcutis Biotherapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis

Dec 06, 2025

XTX Topco Ltd Reduces Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Dec 06, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded to "Buy" Rating by Wall Street Zen - MarketBeat

Dec 06, 2025

Dec 05, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Reaches New 1-Year HighStill a Buy? - MarketBeat

Dec 05, 2025

What risks investors should watch in Arcutis Biotherapeutics Inc. stockRate Cut & Reliable Breakout Forecasts - Newser

Dec 05, 2025

Dec 04, 2025

Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat

Dec 04, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 1,657 Shares - MarketBeat

Dec 04, 2025

Arcutis Biotherapeutics stock hits 52-week high at 31.29 USD - Investing.com

Dec 04, 2025

Arcutis Biotherapeutics stock hits 52-week high at 31.29 USD By Investing.com - Investing.com Canada

Dec 04, 2025

Dec 03, 2025

Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Bioth - GuruFocus

Dec 03, 2025

Assessing Arcutis Biotherapeutics (ARQT) Valuation After Its Strong 1-Year Share Price Surge - Yahoo Finance

Dec 03, 2025

Arcutis Biotherapeutics Insider Sold Shares Worth $302,133, According to a Recent SEC Filing - marketscreener.com

Dec 03, 2025

AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension - Finviz

Dec 03, 2025

Dec 02, 2025

Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock? - sharewise.com

Dec 02, 2025

Arcutis Biotherapeutics: Behind The Big Rally (NASDAQ:ARQT) - Seeking Alpha

Dec 02, 2025

(ARQT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com

Dec 02, 2025

American Century Companies Inc. Purchases 71,815 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Dec 02, 2025

Nov 29, 2025